Clene Inc. And Its Wholly Owned Subsidiary Clene Nanomedicine Inc., A Clinical-Stage Biopharmaceutical Company Announced Topline Study Results From Its Phase 2 Investigational Trial With Cnm-Znag, An Ionic Solution Of Zinc And Silver, For The Treatment Of Non-Hospitalized Acutely Symptomatic Participants Infected With Covid-19.The Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessed The Efficacy And Safety Of Cnm-Znag In Covid-19 Infected Participants In Brazil. Study Participants Were Randomized 1:1:2 To Receive Daily Low Dose Cnm-Znag, High Dose Cnm-Znag, Or Placebo In Addition To Standard Supportive Care For Up To 21 Days. The Primary Endpoint Assessed The Time To Substantial Alleviation Of Covid-19 Symptoms Through 28 Days, Confirmed Over A Continuous Period = 48 Hours, In The Modified Intent-To-Treat (Mitt) Population (All Participants With Pcr Documented Sars-Cov-2 Infection, N=288). No Clinical Benefit Was Observed Versus Placebo. Cnm-Znag Was Safe And Well-Tolerated, And No Safety Signals Were Identified.Rob Etherington, Clene
